Published in J Biol Chem on January 07, 2003
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med (2010) 2.55
Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol (2012) 2.48
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology (2005) 2.46
Endocrine functions of bone in mineral metabolism regulation. J Clin Invest (2008) 2.19
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone (2004) 1.79
Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab (2008) 1.55
CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest (2016) 1.51
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest (2003) 1.42
The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med (2004) 1.28
FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol (2008) 1.28
Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J (2005) 1.26
Viral infection and human disease--insights from minimotifs. Front Biosci (2008) 1.26
Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab (2009) 1.22
Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol (2007) 1.18
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin. Bone (2006) 1.18
Approach to the hypophosphatemic patient. J Clin Endocrinol Metab (2012) 1.16
Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol (2009) 1.14
Molecular pathology of the fibroblast growth factor family. Hum Mutat (2009) 1.06
Biological activity of FGF-23 fragments. Pflugers Arch (2007) 1.03
Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res (2013) 1.00
Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Miner Res (2013) 0.99
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet (2013) 0.96
The rachitic tooth. Endocr Rev (2013) 0.96
Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology (2009) 0.95
An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab (2009) 0.94
Phosphate sensing. Adv Chronic Kidney Dis (2011) 0.93
Mineral (Mal)Adaptation to Kidney Disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol (2015) 0.91
Vitamin D deficiency in chronic liver disease. World J Hepatol (2014) 0.89
Evidence against a direct role of klotho in insulin resistance. Pflugers Arch (2009) 0.87
Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Nutrients (2013) 0.87
Genetic disorders of phosphate regulation. Pediatr Nephrol (2012) 0.86
Protective roles of DMP1 in high phosphate homeostasis. PLoS One (2012) 0.86
Fibroblast growth factor-23 increases mouse PGE2 production in vivo and in vitro. Am J Physiol Renal Physiol (2005) 0.83
Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD. Clin J Am Soc Nephrol (2014) 0.83
Fibroblast Growth Factor 23 Regulation by Systemic and Local Osteoblast-Synthesized 1,25-Dihydroxyvitamin D. J Am Soc Nephrol (2016) 0.82
Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin Endocrinol (Oxf) (2011) 0.82
The structural biology of the FGF19 subfamily. Adv Exp Med Biol (2012) 0.81
FGF23 and Phosphate Wasting Disorders. Bone Res (2013) 0.81
Analysis of Thisbe and Pyramus functional domains reveals evidence for cleavage of Drosophila FGFs. BMC Dev Biol (2010) 0.81
Dentin matrix protein 1 and phosphate homeostasis are critical for postnatal pulp, dentin and enamel formation. Int J Oral Sci (2012) 0.80
Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease. Int J Nephrol (2010) 0.80
Regulation of mineral metabolism by lithium. Pflugers Arch (2013) 0.79
FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets. J Bone Miner Metab (2011) 0.79
The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol (2004) 0.79
FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis. Clin Nephrol (2014) 0.78
Vitamin D metabolism and action in human marrow stromal cells: effects of chronic kidney disease. J Steroid Biochem Mol Biol (2012) 0.77
FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One (2013) 0.77
Combined sequence and sequence-structure based methods for analyzing FGF23, CYP24A1 and VDR genes. Meta Gene (2016) 0.75
Specific ablation of mouse Fam20C in cells expressing type I collagen leads to skeletal defects and hypophosphatemia. Sci Rep (2017) 0.75
Autosomal dominant hypophosphatemic rickets in an 85 year old woman: characterization of her disease from infancy through adulthood. Bone (2012) 0.75
Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Curr Osteoporos Rep (2017) 0.75
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int (2008) 2.59
Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology (2004) 2.40
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology (2004) 2.14
Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology (2007) 1.94
Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem (2004) 1.91
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest (2005) 1.88
Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. Genes Dev (2004) 1.84
Parathyroid hormone is essential for normal fetal bone formation. J Clin Invest (2002) 1.76
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol (2004) 1.67
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Assessment of gene-by-sex interaction effect on bone mineral density. J Bone Miner Res (2012) 1.58
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest (2003) 1.53
CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest (2016) 1.51
The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis (2011) 1.50
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res (2007) 1.38
Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res (2010) 1.37
Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology (2009) 1.33
Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ (2008) 1.33
The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab (2009) 1.32
Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol (2002) 1.32
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology (2003) 1.26
Defective bone mineralization and osteopenia in young adult FGFR3-/- mice. Hum Mol Genet (2003) 1.21
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19
Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest (2003) 1.18
Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum (2006) 1.18
Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res (2012) 1.18
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest (2011) 1.17
Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women. J Bone Miner Res (2013) 1.16
Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res (2009) 1.15
Defects in mesenchymal stem cell self-renewal and cell fate determination lead to an osteopenic phenotype in Bmi-1 null mice. J Bone Miner Res (2010) 1.12
Osteoporosis-related fracture case definitions for population-based administrative data. BMC Public Health (2012) 1.11
Impaired endochondral bone development and osteopenia in Gli2-deficient mice. Exp Cell Res (2004) 1.10
Dietary patterns in Canadian men and women ages 25 and older: relationship to demographics, body mass index, and bone mineral density. BMC Musculoskelet Disord (2010) 1.08
Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc Natl Acad Sci U S A (2008) 1.08
Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. Am J Clin Nutr (2010) 1.06
Parathyroid hormone-related peptide interacts with bone morphogenetic protein 2 to increase osteoblastogenesis and decrease adipogenesis in pluripotent C3H10T 1/2 mesenchymal cells. Endocrinology (2003) 1.04
Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum Mol Genet (2005) 1.04
Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology (2007) 1.02
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone (2008) 1.00
Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J Clin Endocrinol Metab (2013) 0.99
Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype. J Biol Chem (2003) 0.98
Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med (2003) 0.98
Parathyroid hormone regulates fetal-placental mineral homeostasis. J Bone Miner Res (2010) 0.97
Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis (2011) 0.97
Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS. J Clin Densitom (2011) 0.97
Targeted ablation of the chromogranin a (Chga) gene: normal neuroendocrine dense-core secretory granules and increased expression of other granins. Mol Endocrinol (2006) 0.96
LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res (2011) 0.96
In healthy adults, biological activity of vitamin D, as assessed by serum PTH, is largely independent of DBP concentrations. J Bone Miner Res (2014) 0.96
Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab (2012) 0.95
Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A (2012) 0.95
1Alpha,25-dihydroxyvitamin D3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. J Bone Miner Res (2002) 0.95
Early lethality in Hyp mice with targeted deletion of Pth gene. Endocrinology (2007) 0.95
Effects of calcium and of the Vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J Steroid Biochem Mol Biol (2004) 0.94
On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J Bone Miner Res (2008) 0.93
Identification and functional characterization of a novel mutation in the calcium-sensing receptor gene in familial hypocalciuric hypercalcemia: modulation of clinical severity by vitamin D status. J Clin Endocrinol Metab (2007) 0.92
Distinctive anabolic roles of 1,25-dihydroxyvitamin D(3) and parathyroid hormone in teeth and mandible versus long bones. J Endocrinol (2009) 0.92
Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development. Bone (2004) 0.92
Changes in body mass index in Canadians over a five-year period: results of a prospective, population-based study. BMC Public Health (2007) 0.92
Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology (2003) 0.91
The full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. Am J Physiol Renal Physiol (2009) 0.91